Meeting
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.
Authors
Richard D. Kim
Moffitt Cancer Center and Research Institute, Tampa, FL
Richard D. Kim , Nancy Joseph-Ridge , Jichang Du , Janine North , Cathy Warren , Renuka V. Iyer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03790111
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 472)
DOI
10.1200/JCO.2024.42.3_suppl.472
Abstract #
472
Poster Bd #
B17
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben
Poster
2024 ASCO Gastrointestinal Cancers Symposium
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
First Author: Jia Fan
Poster
2024 ASCO Annual Meeting
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.
First Author: Jieer Ying
Poster
2023 ASCO Annual Meeting
A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.
First Author: Li Jingjing